CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $966 | -15.1% | 21,284 | +5.0% | 0.01% | -25.0% |
| Q2 2023 | $1,138 | +9.8% | 20,269 | -11.5% | 0.01% | +14.3% |
| Q1 2023 | $1,036 | +12.9% | 22,912 | +1.5% | 0.01% | 0.0% |
| Q4 2022 | $918 | -99.9% | 22,581 | -6.3% | 0.01% | -36.4% |
| Q3 2022 | $1,574,000 | +126.5% | 24,089 | +110.7% | 0.01% | +120.0% |
| Q2 2022 | $695,000 | -12.0% | 11,432 | -9.2% | 0.01% | +25.0% |
| Q1 2022 | $790,000 | -12.7% | 12,586 | +5.4% | 0.00% | 0.0% |
| Q4 2021 | $905,000 | -14.4% | 11,939 | +26.4% | 0.00% | -33.3% |
| Q3 2021 | $1,057,000 | -14.8% | 9,442 | +23.2% | 0.01% | -14.3% |
| Q2 2021 | $1,241,000 | +56.5% | 7,666 | +17.8% | 0.01% | +75.0% |
| Q1 2021 | $793,000 | +9.8% | 6,509 | +38.0% | 0.00% | 0.0% |
| Q4 2020 | $722,000 | -71.0% | 4,718 | -84.2% | 0.00% | -75.0% |
| Q3 2020 | $2,490,000 | +1006.7% | 29,771 | +676.9% | 0.02% | +1500.0% |
| Q2 2018 | $225,000 | – | 3,832 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |